Literature DB >> 21324899

FGFR3 heterodimerization in achondroplasia, the most common form of human dwarfism.

Lijuan He1, Nadia Shobnam, William C Wimley, Kalina Hristova.   

Abstract

The G380R mutation in the transmembrane domain of fibroblast growth factor receptor 3 (FGFR3) causes achondroplasia, the most common form of human dwarfism. Achondroplasia is a heterozygous disorder, and thus the affected individuals express both wild-type and mutant FGFR3. Yet heterodimerization in achondroplasia has not been characterized thus far. To investigate the formation of FGFR3 heterodimers in cellular membranes, we designed an FGFR3 construct that lacks the kinase domain, and we monitored the formation of inactive heterodimers between this construct and wild-type and mutant FGFR3. The formation of the inactive heterodimers depleted the pool of full-length receptors capable of forming active homodimers and ultimately reduced their phosphorylation. By analyzing the effect of the truncated FGFR3 on full-length receptor phosphorylation, we demonstrated that FGFR3 WT/G380R heterodimers form with lower probability than wild-type FGFR3 homodimers at low ligand concentration. These results further our knowledge of FGFR3-associated bone disorders.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21324899      PMCID: PMC3075674          DOI: 10.1074/jbc.M110.205583

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  28 in total

Review 1.  Cell signaling by receptor tyrosine kinases.

Authors:  J Schlessinger
Journal:  Cell       Date:  2000-10-13       Impact factor: 41.582

2.  Rotational coupling of the transmembrane and kinase domains of the Neu receptor tyrosine kinase.

Authors:  C A Bell; J A Tynan; K C Hart; A N Meyer; S C Robertson; D J Donoghue
Journal:  Mol Biol Cell       Date:  2000-10       Impact factor: 4.138

3.  Novel fibroblast growth factor receptor 3 (FGFR3) mutations in bladder cancer previously identified in non-lethal skeletal disorders.

Authors:  Bas W G van Rhijn; Angela A G van Tilborg; Irene Lurkin; Jacky Bonaventure; Annie de Vries; Jean-Paul Thiery; Theodorus H van der Kwast; Ellen C Zwarthoff; Francois Radvanyi
Journal:  Eur J Hum Genet       Date:  2002-12       Impact factor: 4.246

4.  Skeletal growth in achondroplasia.

Authors:  I V Ponseti
Journal:  J Bone Joint Surg Am       Date:  1970-06       Impact factor: 5.284

Review 5.  Functions of fibroblast growth factors and their receptors.

Authors:  A O Wilkie; G M Morriss-Kay; E Y Jones; J K Heath
Journal:  Curr Biol       Date:  1995-05-01       Impact factor: 10.834

6.  The extracellular domain of fibroblast growth factor receptor 3 inhibits ligand-independent dimerization.

Authors:  Lirong Chen; Jesse Placone; Lawrence Novicky; Kalina Hristova
Journal:  Sci Signal       Date:  2010-11-30       Impact factor: 8.192

Review 7.  The molecular and genetic basis of fibroblast growth factor receptor 3 disorders: the achondroplasia family of skeletal dysplasias, Muenke craniosynostosis, and Crouzon syndrome with acanthosis nigricans.

Authors:  Z Vajo; C A Francomano; D J Wilkin
Journal:  Endocr Rev       Date:  2000-02       Impact factor: 19.871

8.  Mutations in the transmembrane domain of FGFR3 cause the most common genetic form of dwarfism, achondroplasia.

Authors:  R Shiang; L M Thompson; Y Z Zhu; D M Church; T J Fielder; M Bocian; S T Winokur; J J Wasmuth
Journal:  Cell       Date:  1994-07-29       Impact factor: 41.582

9.  Skeletal overgrowth and deafness in mice lacking fibroblast growth factor receptor 3.

Authors:  J S Colvin; B A Bohne; G W Harding; D G McEwen; D M Ornitz
Journal:  Nat Genet       Date:  1996-04       Impact factor: 38.330

10.  Fibroblast growth factor receptor 3 (FGFR3) transmembrane mutation in Crouzon syndrome with acanthosis nigricans.

Authors:  G A Meyers; S J Orlow; I R Munro; K A Przylepa; E W Jabs
Journal:  Nat Genet       Date:  1995-12       Impact factor: 38.330

View more
  19 in total

1.  Quantifying the Interaction between EGFR Dimers and Grb2 in Live Cells.

Authors:  Nuala Del Piccolo; Kalina Hristova
Journal:  Biophys J       Date:  2017-07-19       Impact factor: 4.033

2.  A New Method to Study Heterodimerization of Membrane Proteins and Its Application to Fibroblast Growth Factor Receptors.

Authors:  Nuala Del Piccolo; Sarvenaz Sarabipour; Kalina Hristova
Journal:  J Biol Chem       Date:  2016-12-07       Impact factor: 5.157

Review 3.  Achondroplasia: Development, pathogenesis, and therapy.

Authors:  David M Ornitz; Laurence Legeai-Mallet
Journal:  Dev Dyn       Date:  2017-03-02       Impact factor: 3.780

Review 4.  Transmembrane helix dimerization: beyond the search for sequence motifs.

Authors:  Edwin Li; William C Wimley; Kalina Hristova
Journal:  Biochim Biophys Acta       Date:  2011-09-01

5.  Pathogenic Cysteine Removal Mutations in FGFR Extracellular Domains Stabilize Receptor Dimers and Perturb the TM Dimer Structure.

Authors:  Sarvenaz Sarabipour; Kalina Hristova
Journal:  J Mol Biol       Date:  2016-09-03       Impact factor: 5.469

6.  FGFR3 transmembrane domain interactions persist in the presence of its extracellular domain.

Authors:  Sarvenaz Sarabipour; Kalina Hristova
Journal:  Biophys J       Date:  2013-07-02       Impact factor: 4.033

7.  The A391E mutation enhances FGFR3 activation in the absence of ligand.

Authors:  Fenghao Chen; Catherine Degnin; Melanie Laederich; William A Horton; Kalina Hristova
Journal:  Biochim Biophys Acta       Date:  2011-04-22

Review 8.  Physical-chemical principles underlying RTK activation, and their implications for human disease.

Authors:  Lijuan He; Kalina Hristova
Journal:  Biochim Biophys Acta       Date:  2011-08-05

9.  High-resolution computed tomography temporal bone imaging in achondroplasia.

Authors:  Puneet S Kochar; Priti Soin; Ayah Megahed
Journal:  Proc (Bayl Univ Med Cent)       Date:  2021-01-28

Review 10.  The transition model of RTK activation: A quantitative framework for understanding RTK signaling and RTK modulator activity.

Authors:  Michael D Paul; Kalina Hristova
Journal:  Cytokine Growth Factor Rev       Date:  2019-11-01       Impact factor: 7.638

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.